Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

iECURE

Main focus: Treatment of genetic diseases using in vivo gene editing

Company stage: Pre-clinical

Diseases (gene editing): Liver diseases, other genetic diseases

Genome editing tool: ARCUS Meganuclease

Funding stage: Private

Location: Philidelphia, PA, USA

Website: https://iecure.com/

Gene editing partnerships: Precision Biosciences

iECURE develops novel medicines to treat liver diseases and other genetic diseases. The company has licensed Precision Biosciences' ARCUS Meganuclease gene-editing technology for the development of treatments targeting the PCSK9 gene as well as other targets.

Tags

HashtagiECURE

Company: iECURE
close
Search CRISPR Medicine